Get the Stockscreener App
1.23
2.50%
0.03
Acumen Pharmaceuticals Inc stock is traded at $1.23, with a volume of 566.58K.
It is up +2.50% in the last 24 hours and up +20.59% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$1.20
Open:
$1.22
24h Volume:
566.58K
Relative Volume:
2.36
Market Cap:
$71.48M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.0982
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
+7.89%
1M Performance:
+20.59%
6M Performance:
-30.51%
1Y Performance:
-46.75%
1-Day Range:
$1.15
$1.26
1-Week Range:
$1.15
$1.31
52-Week Range:
$0.8551
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
925-368-8508
Address
427 PARK ST., CHARLOTTESVILLE
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.23 | 71.48M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.54 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
511.92 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.76 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
257.51 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals (NASDAQ:ABOS) Now Covered by Citigroup - Defense World
Citi initiates Acumen Pharmaceuticals stock with buy rating By Investing.com - Investing.com South Africa
Citigroup Initiates Coverage on Acumen Pharmaceuticals (ABOS) wi - GuruFocus
Bank of America Corp DE Boosts Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Cantor Fitzgerald Estimates ABOS FY2026 Earnings - Defense World
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Two Sigma Investments LP Lowers Holdings in Vicor Co. (NASDAQ:VICR) - Defense World
Two Sigma Investments LP Sells 8,239 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Deutsche Bank AG Increases Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Millennium Management LLC Acquires New Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Millennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Cryptocurrency Stocks To Follow Today – May 30th - Defense World
Halozyme to Participate at Upcoming Investor Conferences - The Malaysian Reserve
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Quantisnow
FY2025 EPS Estimates for ABOS Reduced by Cantor Fitzgerald - Defense World
Dimensional Fund Advisors LP Purchases 41,460 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Acumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug development - MSN
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Ovid Therapeutics (OVID) - The Globe and Mail
Acumen Pharmaceuticals’ Earnings Call Highlights Progress in Alzheimer’s Treatment - TipRanks
Tower Research Capital LLC TRC Purchases 16,714 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Transcript : Acumen Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2025 Earnings Call Transcript - Insider Monkey
Barclays PLC Raises Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Barclays PLC Raises Stock Holdings in Babcock & Wilcox Enterprises, Inc. (NYSE:BW) - Defense World
Acumen Pharmaceuticals Q1 2025 Financial Update - TipRanks
ABOS Reports Decline in Cash Reserves to Support Operations | AB - GuruFocus
Earnings call transcript: Acumen Pharmaceuticals Q1 2025 financial results and stock gains - Investing.com Nigeria
Acumen (ABOS) Advances in Alzheimer's Treatment Study | ABOS Sto - GuruFocus
ACUMEN PHARMACEUTICALS Earnings Results: $ABOS Reports Quarterly Earnings - Nasdaq
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Acumen Pharmaceuticals (ABOS) to Release Earnings on Tuesday - Defense World
Acumen Pharmaceuticals Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference - The Manila Times
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - The Manila Times
Upcoming Earnings: Alzheimer's Drug Developer Acumen Pharmaceuticals Reports Q1 Results May 13 - Stock Titan
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - The Malaysian Reserve
Renaissance Technologies LLC Cuts Stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Halozyme to Report First Quarter 2025 Financial and Operating Results - Yahoo Finance
JPMorgan Chase & Co. Has $1.61 Million Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
ABOS stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Finansavisen
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) & Precision BioSciences (NASDAQ:DTIL) - The AM Reporter
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting - The Manila Times
Game-Changing Trial Screening Method: Acumen Advances Alzheimer's Research with pTau217 Innovation - Stock Titan
Charles Schwab Investment Management Inc. Acquires 18,004 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
What is HC Wainwright’s Forecast for ABOS FY2029 Earnings? - Defense World
FY2029 Earnings Forecast for ABOS Issued By HC Wainwright - The AM Reporter
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
2.27%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):